Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Physiomics ( (GB:PYC) ) just unveiled an update.
Physiomics plc announced that its Innovate UK funded project, PREDICT-ONC, has received both regulatory and ethical approval. This project aims to further develop their personalized dosing software which assists clinicians in optimizing chemotherapy dosing for individual patients. The software, initially designed for cancer chemotherapy dosing, has shown potential in predicting GCSF dosing to alleviate chemotherapy-induced neutropenia. Despite delays in the trial start, which were beyond the company’s control, recruitment is set to begin imminently, with minimal impact on the overall timeline anticipated.
More about Physiomics
Physiomics plc is a company that specializes in mathematical modelling, data science, and biostatistics, supporting the development of new therapeutics and personalized medicine solutions. The company utilizes cutting-edge computational tools and bespoke models, such as its proprietary Virtual Tumour technology, to assist biotech and pharma companies in streamlining their drug development processes. Notable clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.
YTD Price Performance: 3.33%
Average Trading Volume: 1,965,113
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.63M
See more data about PYC stock on TipRanks’ Stock Analysis page.
